Prader-Willi Syndrome Therapeutics Market Size, Share, and Industry Analysis, By Drug (Diazoxide choline, Somatropin, and Others), By Age (Children and Adults), By Route of Administration (Oral and Parenteral), By Distribution Channel (Online Pharmacy, Hospital Pharmacy, and Retail Pharmacy), and Regional Forecast, 2026-2034

The global Prader-Willi syndrome therapeutics market is witnessing significant growth due to the rise in the prevalence of Prader-Willi syndrome (PWS). Additionally, the increase in demand for effective treatment and high research and development activities supports the growth of the market. 

The Prader-Willi syndrome (PWS) is a rare genetic disorder in which loss of function of specific genes on chromosome 15. This loss of function leads to various problems, such as physical, developmental, and behavioral problems, including extreme hunger, obesity, and cognitive impairments. Patients can only control this disorder with the help of therapies. 

• For instance, according to the data published on Acadia Pharmaceuticals Inc. in September 2024, approximately 8,000-10,000 patients are suffering from Prader-Willi syndrome in the U.S. This prevalence of Prader-Willi syndrome drives the market growth during the forecast period. 

Prader-Willi Syndrome Therapeutics Market Driver

Rise in Prevalence of Prader-Willi Syndrome Boosts Market Growth

The market expansion is primarily driven by the growing prevalence of Prader-Willi syndrome across the globe. Additionally, new product launches and technological advancements, such as growth hormone therapy, behavioral therapy, etc, help to drive the market growth. Moreover, the rise in demand for advanced treatment, high investment in research and development activities, and government initiatives also support the growth of the Prader-Willi syndrome therapeutics market during the forecast period.

• For instance, in April 2024, Soleno Therapeutics, Inc., a biopharmaceutical company, announced that it had been granted breakthrough therapy designation from the U.S. Food and Drug Administration (FDA) for its product of diazoxide choline for the treatment of adults and children aged 4 years and older with genetically confirmed Prader-Willi syndrome (PWS).

Registry Participants of Prader-Willi Syndrome, By Key Countries 

According to the data published by Molecular Diversity Preservation International in September 2019, in the global PWS registry, the U.S. has the highest number of registry participants at 75% and Canada has the second highest participants, followed by Australia, the U.K., and New Zealand. 

Prader-Willi Syndrome Therapeutics Market Restraint

High Treatment Cost Can Limit Market Growth

The high cost of Prader-Willi syndrome treatment may limit the adoption of treatment in low-middle economic countries. The Prader-Willi syndrome is a lifelong disorder; thus, it has a high annual cost, which may restrict the growth of the market.

• For instance, in March 2025, Soleno Therapeutics, Inc. received approval for a drug that is used in the treatment of Prader-Willi syndrome (PWS) from the U.S. FDA. The annual cost of the drug is USD 466,200.0, and the dose will be given as per the patient's weight. The high annual cost is expected to reduce the adoption of Prader-Willi syndrome therapeutic products, leading to lower market growth.

Prader-Willi Syndrome Therapeutics Market Opportunity

Novel Pipeline Candidates Will Boost Market Growth in Future

In recent years, technological advancement and the rise in demand for advanced treatment options have promoted the growth of the market during the forecast period. Additionally, new product launches and pipeline products for the treatment of Prader-Willi syndrome will boost the growth of the market in the upcoming years. 

• For instance, in April 2024, Harmony Biosciences Holdings Inc. initiated its global Phase 3 registration trial (TEMPO STUDY). The trial aims to check the safety and efficacy of pitolisant as a treatment for children and adults with Prader-Willi syndrome (PWS). This type of advanced pipeline product can result in new product launches, which are expected to boost the market growth during the forecast period. 

Key Insights

The report covers the following key insights:

• Prevalence of Prader-Willi Syndrome, By Key Countries
• New Product Launches/Approvals, By Key Players
• Pipeline Analysis, By Key Players
• Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.)
• Impact of COVID-19 on the Market 

Segmentation

Analysis by Drug

By drug, the market is divided into diazoxide, choline, somatropin, and others.

The somatropin segment held a substantial share of the market. The somatropin drug is used in growth hormone therapy to enhance the Prader-Willi syndrome (PWS) patient’s quality of life. This drug has several advantages, such as improving body composition, growth, and motor benefits. Thus, it enhances the adoption of the drug and boosts the growth of the market. 

• For instance, according to the data published by Pfizer Inc., in June 2023, at the time of growth hormone deficiency or Prader-Willi syndrome, somatropin is prescribed. The somatropin is taken by injection, and currently, it is the only U.S. FDA-approved drug in the market. 

Analysis by Age

Based on age, the market is segmented into children and adults. The children segment is expected to grow significantly during the forecast period. The rise in prevalence of Prader-Willi syndrome in children and the wide range of treatment options available for this age group drive the growth of the market during the forecast period. 

• For instance, according to the data published in StatPearls, in February 2024, Prader-Willi syndrome is a rare disease, and its global prevalence is approximately 1 in every 20,000 to 30,000 births.

Analysis by Route of Administration 

By route of administration, the market is divided into oral and parenteral.

The oral route held a significant share of the market in 2024. The considerable share of the segment is due to the ease of administration and the convenience of the oral route. Additionally, new product launches and the development of new drugs also boost the growth of the market. 

• For instance, in June 2024, Harmony Biosciences Holdings Inc. announced that it received U.S. FDA approval for its new drug application of WAKIX (pitolisant) tablets, leading to the treatment of Prader-Willi syndrome. These types of approvals drive the growth of the market. 

Analysis by Distribution Channel

By distribution channel, the market is divided into online pharmacy, hospital pharmacy, and retail pharmacy.

The retail pharmacy segment held a significant portion of the market. The Prader-Willi syndrome is a lifelong disease and requires frequent medications to control it. The retail pharmacy stores are convenient for the patients as they need to take medications daily. 

• For instance, according to the data published by the Hindustan Times, in November 2022, under 3 years rise in number of pharmacies rose by 27%. Retail pharmacies have a major share in the growth, with 21,374 new retail pharmacy stores opening in 3 years. This rise in the number of retail pharmacy stores is expected to drive the market growth. 

Regional Analysis

By region, the market is divided into North America, Europe, Asia Pacific, the Middle East & Africa, and Latin America.

Request for Customization   to gain extensive market insights.

North America accounted for a substantial share of the global Prader-Willi syndrome therapeutics market in 2024. The region has a high prevalence of Prader-Willi syndrome, which drives the growth of the market. Additionally, the advanced healthcare facilities and infrastructure, leading to early diagnosis and treatment for Prader-Willi syndrome, further boost the growth of the market in this region. Moreover, new product launches and the presence of key market players in this region drive the growth of the market. 

• For instance, in March 2025, Soleno Therapeutics, Inc., a biopharmaceutical company, announced that it received the U.S. Food and Drug Administration approval for the VYKAT XR (diazoxide choline) extended-release tablets used for the treatment of Prader-Willi syndrome. This type of new product launch drives the growth of the market. 

Europe has a considerable share of the Prader-Willi syndrome therapeutics market. The growth of the region is due to the rising prevalence of Prader-Willi syndrome and the high adoption rate for new drugs in this region. Additionally, government support and high investment in research and development also boost the growth of the market during the forecast period.

• For instance, in March 2024, Palobiofarma S.L. announced that it received approval from the U.S. Food and Drug Administration and the European Medicines Agency (EMA) for the orphan drug designation to its novel therapeutic candidate, PBF-999, for the treatment of Prader-Willi Syndrome (PWS). This type of government approval drives the growth of the market in this region. 

The Asia Pacific region is experiencing rapid growth in the global Prader-Willi syndrome therapeutics market, driven by rising prevalence and awareness of Prader-Willi syndrome. 

Key Players Covered

The global Prader-Willi syndrome therapeutics market is consolidated with a few key players. The report includes the profiles of the following key players:

• Novo Nordisk Inc. (Denmark)
• Pfizer Inc. (U.S.)
• Sandoz Inc. (Switzerland)
• Harmony Biosciences Holdings Inc. (U.S.)
• Soleno Therapeutics, Inc. (U.S.)
• Acadia Pharmaceuticals Inc. (U.S.)
• Aardvark Therapeutics, Inc. (U.S.)
• Gedeon Richter Plc (Europe)
• PALOBIOFARMA, S.L. (Spain)
• Tonix Pharmaceuticals Holding Corp. (U.S.)
• ConSynance Therapeutics (New York)

Key Industry Developments

• In November 2024, Soleno Therapeutics, Inc. announced that the U.S. Food and Drug Administration extended the period of new drug application for DCCR extended-release tablets for the treatment of Prader-Willi syndrome (PWS).
• In May 2023, Palobiofarma S.L., a biopharmaceutical company, announced the enrolment of the first three patients in a clinical study to investigate the potential of PBF-999 for the treatment of Prader-Willi Syndrome (PWS).